The Patent Finder

Maintenance fees coming due

Principia Biopharma Inc.

14 maintenance fees come due in the 12 months from Nov 21, 2026, the next on Jan 25, 2027. Unpaid by Jul 26, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5 and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the six month grace period that follows.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusFee dueLapses if unpaidExpiresConfidence
US 11,708,370Solid Forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
In force
Fee due Jan 25, 2027
Lapses if unpaid Jul 26, 2027
 · High confidence
Principia Biopharma Inc.In forceJan 25, 2027Jul 26, 2027High confidence
US 9,090,621Tyrosine Kinase Inhibitors
In force
Fee due Jan 28, 2027
Lapses if unpaid Jul 28, 2027
 · High confidence
Principia Biopharma Inc.In forceJan 28, 2027Jul 28, 2027High confidence
US 10,456,403Salts and Solid Form of a BTK Inhibitor
In force
Fee due Apr 29, 2027
Lapses if unpaid Oct 29, 2027
 · High confidence
Principia Biopharma Inc.In forceApr 29, 2027Oct 29, 2027High confidence
US 11,814,390Crystalline Forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
In force
Fee due May 14, 2027
Lapses if unpaid Nov 15, 2027
 · High confidence
Principia Biopharma Inc.In forceMay 14, 2027Nov 15, 2027High confidence
US 9,187,487Azaindole Derivatives as Tyrosine Kinase Inhibitors
In force
Fee due May 17, 2027
Lapses if unpaid Nov 17, 2027
 · High confidence
Principia Biopharma, Inc.In forceMay 17, 2027Nov 17, 2027High confidence
US 10,485,797Treatment of Pemphigus
In force
Fee due May 26, 2027
Lapses if unpaid Nov 26, 2027
 · High confidence
Principia Biopharma Inc.In forceMay 26, 2027Nov 26, 2027High confidence
US 11,827,656Immunoproteasome Inhibitors
In force
Fee due May 28, 2027
Lapses if unpaid Nov 29, 2027
 · High confidence
Principia Biopharma Inc.In forceMay 28, 2027Nov 29, 2027High confidence
US 10,533,013SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS
In force
Fee due Jul 14, 2027
Lapses if unpaid Jan 14, 2028
 · High confidence
Principia Biopharma Inc.In forceJul 14, 2027Jan 14, 2028High confidence
US 11,872,229Modified Release Formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
In force
Fee due Jul 16, 2027
Lapses if unpaid Jan 18, 2028
 · High confidence
Principia Biopharma Inc.In forceJul 16, 2027Jan 18, 2028High confidence
US 10,538,517Quinolone Derivatives as FGFR Inhibitors
In force
Fee due Jul 21, 2027
Lapses if unpaid Jan 21, 2028
 · High confidence
Principia Biopharma, Inc.In forceJul 21, 2027Jan 21, 2028High confidence
4 more maintenance fees coming due in the 12 months from Nov 21, 2026 · Pro
10 of 14 patents shown. Soonest fee due date first, then patent number.
Pro members see every patent with a maintenance fee coming due: number, title, status, the due date, and the date it lapses if the fee goes unpaid through the grace period.
Upgrade to Pro
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited